DDW 2026 showcased several studies that may meaningfully influence upper GI clinical practice, particularly in Barrett’s esophagus, EoE, gastroparesis, pancreatitis, and metabolic endoscopy.
Among the notable findings, non-endoscopic tools like EsoCheck and EsoGuard showed potential for Barrett’s esophagus screening even in patients without GERD symptoms, while continuous budesonide therapy proved more effective than intermittent treatment for maintaining remission in eosinophilic esophagitis. Researchers also reinforced that symptom improvement alone may not reliably reflect histologic remission in EoE, supporting the continued need for objective monitoring.
Several emerging therapies also drew attention. Tegoprazan demonstrated strong healing rates in erosive esophagitis, including severe disease, while naronapride showed promise as a potential new treatment option for gastroparesis. In metabolic endoscopy, duodenal mucosal resurfacing appeared to reduce post-GLP-1 weight regain after discontinuation of semaglutide or tirzepatide, suggesting endoscopic interventions may eventually complement obesity pharmacotherapy.